Key result
A mimetic peptide (R7W-MP) restores impaired forward trafficking and reduced half-life of L-type calcium channels caused by CACNA1C mutations associated with Brugada syndrome in vitro.
This is a commentary on a study demonstrating that peptide-based targeting of the L-type calcium channel can correct loss-of-function phenotypes in CACNA1 mutations associated with Brugada syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Monasky et al. (2021) conducted an editorial in Brugada syndrome. Mimetic peptide (R7W-MP) was evaluated. A mimetic peptide (R7W-MP) restores impaired forward trafficking and reduced half-life of L-type calcium channels caused by CACNA1C mutations associated with Brugada syndrome in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: